In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $160.00. The company’s shares closed last Monday at $77.33, close to its 52-week low of $68.04.
According to TipRanks.com, Yang has 0 stars on 0-5 stars ranking scale with an average return of -6.4% and a 32.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Xeris Pharmaceuticals, and Magenta Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sarepta Therapeutics with a $134.00 average price target, representing an 88.1% upside. In a report released today, Needham also assigned a Buy rating to the stock with a $166.00 price target.
Sarepta Therapeutics’ market cap is currently $5.65B and has a P/E ratio of -10.00. The company has a Price to Book ratio of 7.52.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Most recently, in March 2021, Kathleen Behrens, a Director at SRPT sold 5,000 shares for a total of $428,800.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.